Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 956

Sort by

Sort Order Select

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan

Blood (2021) 137 (17): 2337–2346.

https://doi.org/10.1182/blood.2020009499

Published: 2021

Includes: Supplemental data

Journal Articles

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen Walsh, Diana Chin, Leopoldo Luistro, Jocelin Joseph, Gerald Chu, Kathryn Packman, Shoba Shetty, Yusri Elsayed, Ricardo Attar, François Gaudet

Blood (2020) 135 (15): 1232–1243.

https://doi.org/10.1182/blood.2019003342

Published: 2020

Includes: Supplemental data

Journal Articles

Supercharging your CAR

Sneha Ramakrishna, Kara L. Davis

Blood (2020) 135 (9): 593–594.

https://doi.org/10.1182/blood.2019004469

Published: 2020

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

Journal Articles

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Muna Qayed, MD MSc, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, MD, John T. Horan, MDMPH, Bruce R. Blazar, MD, Leslie Kean, MD PhD

Blood (2019) 134 (Supplement_1): 596.

https://doi.org/10.1182/blood-2019-131955

Published: 2019

Journal Articles

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Stephan M Tirier, PhD, Jan-Philipp Mallm, PhD, Nicola Casiraghi, PhD, Hana Susak, PhD, Nicola Giesen, MD, Alexandra M Poos, PhD, Katharina Bauer, Anja Baumann, Lukas John, MD, Jing Xu, PhD, Lara Klett, MSc, Carsten Müller-Tidow, MD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Niels Weinhold, PhD, Oliver Stegle, PhD, Karsten Rippe, PhD, Marc S. Raab, MD

Blood (2019) 134 (Supplement_1): 571.

https://doi.org/10.1182/blood-2019-128625

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Jing Yang, PhD, Jan L. Hillson, MD, Kristi L. Manjarrez, Jennifer R. Wiley, DRSc, Gary D. Means, PhD, Stacey R. Dillon, PhD, Stanford L. Peng, MD,PhD

Blood (2019) 134 (Supplement_1): 372.

https://doi.org/10.1182/blood-2019-126034

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger

Blood (2019) 134 (Supplement_1): 143.

https://doi.org/10.1182/blood-2019-122895

Published: 2019

Journal Articles

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Alexander I. Ngwube, MD, Niketa C. Shah, MD, David Jacobsohn, MD, Edward Dela Ziga, MD, Shalini Shenoy, MD

Blood (2019) 134 (Supplement_1): 370.

https://doi.org/10.1182/blood-2019-126405

Published: 2019

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Federico Simonetta, MD PhD, Toshihito Hirai, MD PhD, Juliane K. Lohmeyer, MD, Kristina Maas-Bauer, MD, Maite Alvarez, PhD, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, PhD, Samuel Haile, PhD, Crystal L. Mackall, MD, Robert S. Negrin, MD

Blood (2019) 134 (Supplement_1): 867.

https://doi.org/10.1182/blood-2019-122515

Published: 2019

Journal Articles

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune Modulators

Ahmad Faisal Karim, PhD, Anthony R. Soltis, PhD, Nadia P Ewing, MD, Clifton L. Dalgard, PhD, Matthew D. Wilkerson, PhD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 160.

https://doi.org/10.1182/blood-2019-124855

Published: 2019

Journal Articles

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

Saba Ghassemi, PhD, Roddy S O'Connor, PhD, Selene Nunez-cruz, PhD, Jai Patel, John Leferovich, Michael C. Milone

Blood (2019) 134 (Supplement_1): 4436.

https://doi.org/10.1182/blood-2019-131147

Published: 2019

Journal Articles

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Estelle V Cervantes, Justin C. Boucher, PhD, Sae Bom Lee, Kristen Spitler, Kayla Reid, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4438.

https://doi.org/10.1182/blood-2019-122752

Published: 2019

NARROW

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Supercharging your CAR

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune Modulators

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only